INTRODUCTION {#s1}
============

Fluoropyrimidines, such as 5-fluorouracil (5-FU), and the oral prodrugs capecitabine and tegafur have been widely used in the treatment of a variety of solid cancers for a long time, especially colorectal cancer (CRC) \[[@R1]--[@R3]\]. Fluoropyrimidine drugs themselves have no anti-tumor activity, but they can be metabolized into fluorodeoxyuridine monophosphate (FdUMP). FdUMP could further form the ternary complex with 5, 10-methylenetetrahydrofolate (5, 10-MTHF) and thymidylate synthase (TS), thereby inhibiting the activity of TS. This prevents the conversion of 2′-deoxyuridine-5′-monophosphate into 2′- deoxythymidine-5′-monophosphate, the latter of which is an essential precursor for DNA synthesis \[[@R4]\]. There are many factors influencing the metabolism of fluoropyrimidines, among them, the polymorphism of metabolism-related genes of fluoropyrimidine is one of the most pivotal factors.

Methylenetetrahydrofolate reductase (MTHFR), the most critical enzyme in folate-metabolizing pathway, catalyzes the irreversible conversion of 5, 10- methylenetetrahydrofolate (5, 10-MTHF) to 5-methyltetrahydrofolate, and reduces the amount of 5, 10-MTHF available for binding to FdUMP and TS \[[@R5]\]. Therefore, MTHFR plays a key role in the catabolism of fluoropyrimidines to the active metabolites. The activity of MTHFR may be an important factor for predicting the clinical response to fluoropyrimidine-based chemotherapy. The coding gene *MTHFR* locates in chromosome 1p36.3, and is highly polymorphic \[[@R6]\]. Two common functional polymorphisms in the *MTHFR* gene, C677T (rs1801133, A222V) and A1298C (rs1801131, E429A), have been identified the main variants affecting the activity of this enzyme \[[@R7], [@R8]\]. Thus, *MTHFR* C677T and A1298C polymorphisms are potential predictors for the clinical response to fluoropyrimidine-based chemotherapy.

Although theoretically *MTHFR* gene polymorphisms are closely related to the efficacy of fluoropyrimidines, in fact the available evidence from the genetic association studies in clinic was weak and the published results were inconsistent. This discordance also existed in the existing meta-analysis. The systematic review conducted by Elias Zintzaras and colleagues indicated that *MTHFR* C677T and A1298C gene polymorphisms could not be considered as reliable predictors of response to fluorouracil-based chemotherapy in patients with colorectal cancer \[[@R9]\]. However, another meta-analysis in colorectal and esophageal cancer, as well as a systematic review in gastric cancer, showed the opposite result \[[@R10], [@R11]\]. In this account, an update systematic review and meta-analysis containing 11 novel studies was carried out to further comprehensively estimate the correlation of MTHFR polymorphisms with the clinical response to fluoropyrimidine-based chemotherapy in CRC patients.

RESULTS {#s2}
=======

Study characteristics {#s2_1}
---------------------

This study is based on meta-analysis of observational studies in epidemiology (MOOSE). The flowchart of study selection was shown in Figure [1](#F1){ref-type="fig"}. A total of 295 potential relevant publications were retrieved from the databases. According to the inclusion/exclusion criteria, data from 21 studies that investigated the association between *MTHFR* C677T or A1298C polymorphisms and response to fluoropyrimidine-based chemotherapy in CRC patients were collected for the meta-analysis \[[@R12]--[@R32]\]. The characteristics of 21 eligible studies were shown in Table [1](#T1){ref-type="table"}. Studies were published between 1999 and 2016, and sample sizes ranged from 43 to 238. Seven of twenty-one studies (33.3%) were conducted prospectively (Table [1](#T1){ref-type="table"}). Of these publications, studies were conducted in three different ethnicities: Caucasian (fifteen studies), Asian (five studies), and mixed crowd (one study). All studies reported used fluoropyrimidines as treatment along with a combination of other interventions, such as folinic acid. Among the publications, 21 studies including 2118 patients reported tumor response events associated with *MTHFR* C677T polymorphism, and 13 studies provided 1496 patients for testing the association of *MTHFR* A1298C variant with response to chemotherapy (Table [1](#T1){ref-type="table"}). In thirteen studies, responders were defined as patients with complete response (CR, disappearance of the disease), partial response (PR, decrease at least 50% in tumor load of the lesions) or stable disease (SD, without response or progression). In the remaining studies, responders were defined based on tumor regression grading (TRG), survival or early recurrence. Among them, the classification criteria of TRG was shown as follows: TRG1, absence of residual cancer and extensive fibrosis; TRG2, rare residual cancer cells scattered through the fibrosis; TRG3, increased residual cancer cells but fibrosis still predominating; TRG4, residual cancer outgrowing fibrosis; TRG5, absence of regressive changes. The quality of each eligible article was assessed by the Newcastle-Ottawa Scale (NOS), and all studies received a high NOS score (≥5, data not shown).

![Flow diagram of study selection](oncotarget-09-31291-g001){#F1}

###### Characteristics of the studies included in the meta-analysis

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study (year)                      Ethnicity     Clinical data gathering   Patients, *n* (male%)   Age, mean (range)   Chemotherapy regimens                                                    Definition of responders               Definition of non- responders   MTHFR SNP      Method of MTHFR SNP analysis   HWE reported and in equilibrium?   Ref.
  --------------------------------- ------------- ------------------------- ----------------------- ------------------- ------------------------------------------------------------------------ -------------------------------------- ------------------------------- -------------- ------------------------------ ---------------------------------- ------
  Wisotzkey JD, *et al*. (1999)     Caucasian     Retrospective             51 (--)                 --                  5-Fu *+* folinic acid                                                    Alive without any evidence of cancer   Dead or alive with cancer       C677T          PCR-RFLP                       Not reported                       12

  Cohen V, *et al*. (2003)          Mixed crowd   Retrospective             43 (62.8)               59 (43--70)         5-Fu/LV, Capecitabine, UFT                                               CR, PR                                 SD, PD                          C677T          PCR-\                          Not reported                       13
                                                                                                                                                                                                                                                                                       Electrophoresis                                                   

  Etienne MC, *et al*. (2004)       Caucasian     Retrospective             98 (58.2)               64 (40--82)         5-Fu *+* folinic acid                                                    CR, PR                                 SD, PD                          C677T A1298C   PCR-HRM                        Yes                                14

  Jakobsen A, *et al*. (2005)       Caucasian     Retrospective             88 (57)                 62 (--)             5-Fu *+* leucovorin                                                      CR, PR                                 SD, PD                          C677T A1298C   PCR-RFLP                       Not reported                       15

  Marcuello E, *et al*. (2006)      Caucasian     Prospective               94 (72)                 68 (43--83)         5-Fu *+* Irinotecan, 5-Fu *+* leucovorin *+* oxaliplatin                 CR, PR                                 SD, PD                          C677T A1298C   RT-PCT                         Not reported                       16

  Suh KW, *et al*. (2006)           Asian         Retrospective             54 (55.6)               57.8 (35--79)       FOLFOX                                                                   CR, PR, SD                             PD                              C677T          sequencing                     Yes                                17

  Terrazzino S, *et al*. (2006)     Caucasian     Retrospective             125 (64)                60 (31--79)         5-FU,\                                                                   TRG 1-2                                TRG 3-5                         C677T A1298C   PCR-\                          Yes                                18
                                                                                                                        5-Fu *+* leucovorin *+* oxaliplatin, 5-FU *+* CARBO                                                                                                            Electrophoresis                                                   

  Capitain O, *et al*. (2008)       Caucasian     Retrospective             76 (60.5)               71 (39--88)         5-Fu *+* leucovorin                                                      CR, PR                                 SD, PD                          C677T A1298C   sequencing                     Yes                                19

  Huang MY, *et al*. (2008)         Asian         Prospective               201 (58.7)              62\                 5-Fu *+* leucovorin                                                      Non-early recurrence                   Early recurrence                C677T          PCR-RFLP                       Not reported                       20
                                                                                                    (33--75)                                                                                                                                                                                                                                             

  Ruzzo A, *et al*. (2008)          Caucasian     Prospective               146 (54.8)              61 (38--75)         FOLFIRI                                                                  CR, PR                                 SD, PD                          C677T A1298C   PCR-RFLP                       Yes                                21

  Balboa E, *et al*. (2010)         Caucasian     Prospective               65 (76.9)               64\                 5-Fu/Capecitabine                                                        TRG 1-2                                TRG 3-5                         C677T A1298C   SnapShot                       Yes                                22
                                                                                                    (37--85)                                                                                                                                                                                                                                             

  Etienne MC, *et al*. (2010)       Caucasian     Prospective               117 (55.6)              67 (31--80)         FOLFOX                                                                   CR, PR                                 SD, PD                          C677T A1298C   PCR-HRM                        Yes                                23

  Cecchin E, *et al*. (2011)        Caucasian     Retrospective             238 (66.8)              61\                 5-Fu, 5-Fu *+* platinum/\                                                TRG 1-2                                TRG 4-5                         C677T A1298C   TaqMan assay                   No                                 24
                                                                                                    (20--79)            irinotecan/gefitinib                                                                                                                                                                                                             

  Lamas MJ, *et al*. (2011)         Caucasian     Retrospective             72 (69.4)               66.5 (32--80)       FOLFOX, FOLFOX *+* Cetuximab, FOLFOX *+* Bevacizumab                     CR, PR, SD                             PD                              C677T A1298C   SnapShot                       Yes                                25

  Hu-Lieskovan S, *et al*. (2011)   Caucasian     Retrospective             130 (57)                61\                 5-Fu *+* Cetuximab,\                                                     TRG 1                                  TRG 2-5                         C677T A1298C   PCR-RFLP                       Not reported                       26
                                                                                                    (33--83)            Capecitabine *+* Cetuximab, Capecitabine *+* Oxaliplatin *+* Cetuximab                                                                                                                                                           

  Budai B, *et al*. (2012)          Caucasian     Prospective               85 **(--)**             \_                  FOLFIRI *+* bevacizumab                                                  CR, PR                                 SD, PD                          C677T          PCR-RFLP                       Yes                                27

  Chai HN, *et al*. (2012)          Asian         Prospective               73 (61.6)               59 (24--87)         FOLFOX                                                                   CR, PR                                 SD, PD                          C677T          sequencing                     Yes                                28

  Zhao J, *et al*. (2012)           Asian         Retrospective             154 (58.4)              56 (30--75)         FOLFOX, XELOX, FOLFIRI                                                   CR, PR                                 SD, PD                          C677T A1298C   sequencing                     Not reported                       29

  Lamas MJ, *et al*. (2012)         Caucasian     Retrospective             93 (73.1)               67 (39--86)         5-Fu                                                                     TRG 1-2                                TRG 3-5                         C677T A1298C   SnapShot                       Yes                                30

  Kumamoto K, *et al*. (2013)       Asian         Retrospective             63 (**65.1)**           65 (32--84)         FOLFOX                                                                   CR, PR                                 SD, PD                          C677T          PCR-RFLP                       Not reported                       31

  Boudaoud K, *et al*. (2016)       Caucasian     Retrospective             52 (59.6)               50.8\               5-Fu *+* FA,\                                                            pCR *+* downstaging                    \_                              C677T          PCR-RFLP                       Not reported                       32
                                                                                                    (23--70)            Capecitabine                                                                                                                                                                                                                     
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*HWE*, Hardy-Weinberg equilibrium; *CR*, complete response; *PR*, partial response; *SD*, stable disease; *PD*, progressive disease; *pCR*, pathologic complete response; *TRG*, tumor regression grading; *PCR*, polymerase chain reaction; *RFLP*, restriction fragment length polymorphism; *HRM*, High Resolution Melting.

Association of *MTHFR* C677T polymorphism with response to fluoropyrimidine-based chemotherapy {#s2_2}
----------------------------------------------------------------------------------------------

The main results of meta-analysis and heterogeneity test for *MTHFR* C677T were summarized in Table [2](#T2){ref-type="table"}. Overall, no significant association was found between *MTHFR* C677T polymorphism and response to fluoropyrimidine-based chemotherapy under all three genetic models: allele model (OR = 0.93, 95% CI = 0.78--1.12) (Figure [2A](#F2){ref-type="fig"}), dominant model (OR = 0.79, 95% CI = 0.63--1.00) ([Supplementary Figure 1A](#SD1){ref-type="supplementary-material"}), and recessive model (OR = 1.20, 95% CI = 0.91--1.57) ([Supplementary Figure 2A](#SD1){ref-type="supplementary-material"}). The Q-statistic and I^2^ index in the three models indicated moderate heterogeneity in allele and dominant models (25% \< I^2^ \< 50%), and no significant heterogeneity under recessive model (*P~Q~* = 0.151, I^2^ = 24.9%). When stratified by ethnicity, study type, clinical outcome and chemotherapy regimen, only the retrospective study subgroup in dominant model showed a significant association (OR = 0.69, 95% CI = 0.53--0.90). Moreover, the heterogeneity only reduced simultaneously when stratified by ethnicity under allele model (Table [2](#T2){ref-type="table"}).

###### Odds ratio with the corresponding 95% confidence interval, heterogeneity results, Egger' test and Begg' test for genetic contrasts of *MTHFR* C677T

  Models            Population   No. studies         Random effects OR (95% CI)   *P*-value (*Q*-test)   I^2^ (%)   Egger' test   Begg' test
  ----------------- ------------ ------------------- ---------------------------- ---------------------- ---------- ------------- ------------
  T versus C        All          20                  0.93 (0.78--1.12)            0.064                  34.8       0.766         0.721
  Caucasians        15           0.95 (0.78--1.15)   0.144                        28.5                   0.713      0.692         
  Asians            4            0.73 (0.50--1.06)   0.404                        0.0                    0.325      0.308         
  Prospective       7            0.96 (0.73--1.27)   0.212                        28.4                   0.102      0.230         
  Retrospective     13           0.92 (0.72--1.18)   0.060                        41.1                   0.369      0.760         
  ORR               12           0.98 (0.77--1.24)   0.114                        34.6                   0.978      0.373         
  TRG               5            0.87 (0.57--1.35)   0.029                        63.0                   0.703      0.806         
  5-Fu *+* FA       5            0.98 (0.71--1.34)   0.568                        0.0                    0.156      0.462         
  FOLFOX            4            0.83 (0.46--1.50)   0.042                        63.4                   0.058      0.308         
  Dominant model    All          21                  0.79 (0.63--1.00)            0.117                  27.8       0.884         0.928
  Caucasians        15           0.79 (0.60--1.05)   0.108                        32.5                   0.408      0.692         
  Asians            5            0.68 (0.46--1.02)   0.700                        0.0                    0.313      0.806         
  Prospective       7            0.99 (0.67--1.47)   0.179                        32.7                   0.167      0.101         
  Retrospective     14           0.69 (0.53--0.90)   0.306                        13.4                   0.273      0.189         
  ORR               13           0.85 (0.62--1.15)   0.156                        28.7                   0.854      0.951         
  TRG               5            0.65 (0.37--1.11)   0.071                        53.6                   0.757      1.000         
  5-Fu *+* FA       5            0.75 (0.50--1.14)   0.733                        0.0                    0.622      0.806         
  FOLFOX            4            0.78 (0.35--1.73)   0.056                        60.4                   0.164      0.734         
  Recessive model   All          20                  1.20 (0.91--1.57)            0.151                  24.9       0.389         0.315
  Caucasians        15           1.26 (0.88--1.82)   0.139                        29.0                   0.543      0.322         
  Asians            4            0.67 (0.26--1.76)   0.464                        0.0                    0.519      0.308         
  Prospective       7            0.92 (0.58--1.47)   0.641                        0.0                    0.481      0.368         
  Retrospective     13           1.44 (0.89--2.33)   0.085                        37.3                   0.351      0.583         
  ORR               12           1.22 (0.78--1.92)   0.195                        25.3                   0.320      0.537         
  TRG               5            1.28 (0.63--2.61)   0.077                        52.5                   0.570      0.462         
  5-Fu *+* FA       5            1.82 (0.73--4.51)   0.191                        34.6                   0.491      0.462         
  FOLFOX            4            0.88 (0.35--2.25)   0.268                        23.9                   0.132      0.089         

*ORR*, objective response rate (CR, PR, SD and PD) as end point; *TRG*, tumor regression grading as end point; *5-Fu + FA,* chemotherapy regimens including 5-Fu *+* folinic acid and 5-Fu *+* leucovorin; *FOLFOX*, fluorouracil *+* leucovorin *+* oxaliplatin.

![Forest plot (**A**) and sensitivity analysis (**B**) for the allele contrast of *MTHFR* C677T polymorphism and response to fluoropyrimidine-based chemotherapy.](oncotarget-09-31291-g002){#F2}

Association of *MTHFR* A1298C polymorphism with response to fluoropyrimidine-based chemotherapy {#s2_3}
-----------------------------------------------------------------------------------------------

For the association between *MTHFR* A1298C polymorphism and response to fluoropyrimidine-based chemotherapy, the pooled results from meta-analysis showed no significant association in all of the three genetic models (Table [3](#T3){ref-type="table"}, Figure [3A](#F3){ref-type="fig"}, and [Supplementary Figures 3A](#SD1){ref-type="supplementary-material"} and [4A](#SD1){ref-type="supplementary-material"}). Moderate heterogeneity was observed in allele contrast and dominant model (25% \< I^2^ \< 50%; Table [3](#T3){ref-type="table"}), but not in recessive model (*P~Q~* = 0.247, I^2^ = 20%; Table [3](#T3){ref-type="table"}). In the subgroup analysis according to ethnicity, study type, clinical outcome and chemotherapy regimen, the association was still not significant except in the "5-Fu *+* FA" group of allele contrast (OR = 0.63, 95% CI = 0.41--0.97; Table [3](#T3){ref-type="table"}). Moreover, the heterogeneity was evidently eliminated in the retrospective study group, TRG group and "5-Fu *+* FA" treatment group of allele and dominant models (*P~Q~* \> 0.1, I^2^ \< 25%; Table [3](#T3){ref-type="table"}).

###### Odds ratio with the corresponding 95% confidence interval, heterogeneity results, Egger' test and Begg' test for genetic contrasts of *MTHFR* A1298C

  Models            Population   No. studies         Random effects OR (95% CI)   *P*-value (*Q*-test)   I^2^ (%)   Egger' test   Begg' test
  ----------------- ------------ ------------------- ---------------------------- ---------------------- ---------- ------------- ------------
  C versus A        All          12                  0.96 (0.76--1.21)            0.098                  36.7       0.376         0.244
  Caucasians        12           0.96 (0.76--1.21)   0.098                        36.7                   0.376      0.244         
  Asians            0                                                                                                             
  Prospective       4            1.17 (0.73--1.86)   0.067                        58.0                   0.997      1.000         
  Retrospective     8            0.87 (0.68--1.12)   0.314                        14.8                   0.269      0.386         
  ORR               7            0.90 (0.61--1.33)   0.033                        56.2                   0.394      0.548         
  TRG               5            1.02 (0.79--1.33)   0.489                        0.0                    0.865      0.806         
  5-Fu *+* FA       3            0.63 (0.41--0.97)   0.670                        0.0                    0.490      1.000         
  Dominant model    All          13                  0.97 (0.73--1.28)            0.123                  32.4       0.360         0.428
  Caucasians        12           0.98 (0.72--1.33)   0.093                        37.3                   0.335      0.451         
  Asians            1                                                                                                             
  Prospective       4            1.20 (0.62--2.31)   0.041                        63.7                   0.965      0.734         
  Retrospective     9            0.90 (0.68--1.19)   0.403                        3.9                    0.129      0.175         
  ORR               8            0.86 (0.57--1.30)   0.070                        46.5                   0.555      0.711         
  TRG               5            1.15 (0.81--1.64)   0.496                        0.0                    0.540      0.806         
  5-Fu *+* FA       3            0.62 (0.37--1.07)   0.962                        0.0                    0.271      0.296         
  Recessive model   All          12                  0.87 (0.58--1.30)            0.247                  20.0       0.177         0.134
  Caucasians        12           0.87 (0.58--1.30)   0.247                        20.0                   0.177      0.134         
  Asians            0                                                                                                             
  Prospective       4            1.40 (0.45--4.41)   0.146                        44.3                   0.168      0.734         
  Retrospective     8            0.78 (0.44--1.38)   0.335                        12.2                   0.881      0.536         
  ORR               7            1.05 (0.45--2.47)   0.197                        30.3                   0.438      0.368         
  TRG               5            0.80 (0.42--1.51)   0.305                        17.2                   0.500      0.462         
  5-Fu *+* FA       3            0.49 (0.13--1.86)   0.235                        31.0                   0.260      1.000         

*ORR*, objective response rate (CR, PR, SD and PD) as end point; *TRG*, tumor regression grading as end point; *5-Fu + FA,* chemotherapy regimens including 5-Fu *+* folinic acid and 5-Fu *+* leucovorin.

![Forest plot (**A**) and sensitivity analysis (**B**) for the allele contrast of *MTHFR* A1298C polymorphism and response to fluoropyrimidine-based chemotherapy.](oncotarget-09-31291-g003){#F3}

Sensitivity analysis and publication bias {#s2_4}
-----------------------------------------

The sensitivity of the overall results was assessed by sequential omission of individual studies. As indicated in Figure [2B](#F2){ref-type="fig"}, Figure [3B](#F3){ref-type="fig"} and [Supplementary Figures 1](#SD1){ref-type="supplementary-material"}--[4B](#SD1){ref-type="supplementary-material"}, there were no individual studies in all three models (allele model, dominant model and recessive model) that could significantly influence the combined results, indicating the reliability and stability of our results. In addition, we used Egger\'s test and Begg\'s test to assess the publication bias. As shown in Table [2](#T2){ref-type="table"} and Table [3](#T3){ref-type="table"}, the *P* values were all greater than 0.05 in both tests under all of the three genetic models of *MTHFR* C677T or A1298C polymorphisms, suggesting no indication of significant publication bias.

Cumulative meta-analysis in allele model of *MTHFR* C677T polymorphism exhibited that the OR increased from 0.72 in 1999 to 1.4 in 2003, and then reduced to 0.89 in 2008, followed by fluctuating around 1.0, but did not exceed 1.0 (Figure [4A](#F4){ref-type="fig"}). The association remained nonsignificant throughout the whole period. For the allele contrast of *MTHFR* A1298C polymorphism, the OR showed an upward trend overall (from 0.50 in 2004 to 0.96 in 2012), with fluctuation in the period of 2006--2012. The significant association just existed before 2005 (Figure [4B](#F4){ref-type="fig"}).

![Cumulative meta-analysis for the allele contrast of *MTHFR* C677T (**A**) and A1298C (**B**) polymorphisms.](oncotarget-09-31291-g004){#F4}

DISCUSSION {#s3}
==========

The association of *MTHFR* polymorphisms with the clinical response to fluoropyrimidine-based chemotherapy in CRC patients is still controversial. Etienne-Grimaldi et al. has demonstrated that *MTHFR* genotypes linked to the clinical response to fluoropyrimidine-based treatment. Importantly, the score of favourable *MTHFR* alleles (677T and 1298C) was positively linked to response, with response rates of 37.1%, 53.3%, 62.5% and 80.0% in CRC patients bearing no, one, two or three favourable alleles, respectively \[[@R23]\]. While this correlation was not replicated in some other studies, which showed that no significant differences were identified between the polymorphisms of *MTHFR* and the efficacy of fluoropyrimidine-based treatment \[[@R30], [@R31]\]. Similarly, this discordance was also present in the *in vitro* studies \[[@R33], [@R34]\]. To quantitatively and comprehensively evaluate the effect of *MTHFR* C677T and A1298C polymorphisms on fluoropyrimidine-based chemotherapy in CRC patients, a meta-analysis including 21 studies was performed. The results of present meta-analysis suggested that there was no significant association between *MTHFR* C677T or A1298C polymorphisms and the clinical response to fluoropyrimidine-based chemotherapy in patients with CRC under allele, dominant and recessive models. Of note, when stratified by study type and chemotherapy regimen, the significant association could be observed in the retrospective study group of *MTHFR* C677T dominant model and the "5-Fu *+* FA" treatment group of *MTHFR* A1298C allele contrast. However, taking into account the authority of retrospective studies and the small number of studies included in the analysis, the results of these subgroup analysis require further assessed more scientifically.

The present meta-analysis has some limitations that need to be addressed. First, due to the lack of original data, our analysis was based on OR values without adjustment for other covariates such as age, gender, which may result in relatively low power to estimate the real association. This is also a general problem of meta-analysis when pooling data from primary studies. Second, some subgroup analysis, especially stratified by chemotherapy regimen, had insufficient statistical power to detect the association for the limited number of included studies. Finally, heterogeneity is a noticeable problem in this meta-analysis. Although it was moderate, potential sources of heterogeneity were not found absolutely by the sensitivity analysis and stratification analysis. When stratified by ethnicity, study type, clinical outcome and chemotherapy regimen, the heterogeneity just decreased simultaneously in both Caucasians and Asians subgroups under the allele model of *MTHFR* C677T (Table [2](#T2){ref-type="table"}).

There are many factors contributing to the heterogeneity among studies except for ethnicity, study type, clinical outcome and chemotherapy regimen. Folate intake status is one of the most important influence factors \[[@R35], [@R36]\]. MTHFR is a critical enzyme in folate-metabolizing pathway, and folate status may affect the association of *MTHFR* polymorphisms with response to fluoropyrimidine-based treatment through gene-nutrition interaction. However, this effect was not assessed adequately in this study due to the unavailability of original data. The administration mode of fluoropyrimidines is also a factor influencing the efficacy of the agents. Fluoropyrimidines act in two different ways. Bolus fluoropyrimidines incorporate into RNA and preclude protein synthesis, while continuous infusion may have a preferential effect on TS \[[@R4]\]. The eligible studies in this meta-analysis used both modes of fluoropyrimidines administration. Additionally, fluoropyrimidines were combined with multiple chemotherapeutic agents in the studies included. Different combination regimens may cause the diversities in efficacy, thus contributing to the heterogeneity among studies.

In summary, the current meta-analysis found that *MTHFR* C677T and A1298C polymorphisms could not be considered as reliable factors for predicting the clinical response to fluoropyrimidine-based chemotherapy in patients with CRC. However, the results in present meta-analysis should be interpreted with cautiously due to the moderate heterogeneity in some genetic models. Therefore, well-designed prospective studies based on larger sample sizes are warranted to validate the present findings. Additionally, in view of the fact that fluoropyrimidines exert their effects through a multistep, multigenic cascade, hence, composite pharmacogenomics analysis may be more precise for efficacy prediction of fluoropyrimidine-based regimens.

MATERIALS AND METHODS {#s4}
=====================

Search strategy {#s4_1}
---------------

We searched PubMed, Embase and Web of Science databases from inception up to May 2017 using a combination of the following terms: "MTHFR" or "methylenetetrahydrofolate reductase", "pharmacogenetic" or "polymorphism" or "genotype" or "variant" or "variation" or "mutant", "fluorouracil" or "5-Fu" or "capecitabine" or "tegafur" or "fluoropyrimidine", and "colon cancer" or "rectal cancer" or "colorectal cancer" or "CRC". The search was restricted to articles in English-language. To identify more potentially relevant studies, a manual search for references cited in the eligible articles was also performed.

Inclusion and exclusion criteria {#s4_2}
--------------------------------

The eligible studies in this meta-analysis fulfill the following inclusion criteria: (a) studies involving any type of colorectal cancer; (b) using chemotherapy regimens containing 5-Fu, capecitabine or tegafur; (c) using validated molecular methods for genotyping; (d) providing information on *MTHFR* polymorphism or estimated genetic effects on response to treatment. No restrictions were imposed on the design of the studies, which could have been prospective or retrospective studies. Studies investigating susceptibility, progression, or severity, and the case reports, letters, conference abstracts, meta-analysis, and reviews were excluded.

Data extraction {#s4_3}
---------------

Full reports of relevant studies were retrieved and independently extracted by two investigators (Yuan Zhang and Jun-Lan Chuan). The extracted data included first author\'s name, publication year, ethnicity of the study population, study design, distribution of gender and age in patients, clinical outcomes investigated, chemotherapy regimen, clinical response, genotype distribution of *MTHFR* and genotyping methods. Any discrepancies in data extraction were resolved by consensus.

Assessment of study quality {#s4_4}
---------------------------

The quality of the included studies was evaluated independently by two reviewers according to the Newcastle-Ottawa Scale (NOS) \[[@R37]\]. The NOS includes three parameters of quality for studies: selection of the study population, comparability of subjects, and exposure assessment, with scores ranging from 0 to 9. NOS scores of 0--4 and 5--9 were considered as low and high-quality studies, respectively.

Statistical analysis {#s4_5}
--------------------

The strength of association between the *MTHFR* C677T or A1298C polymorphisms and clinical response was assessed by odds ratio (OR) and corresponding 95% confidence interval (CI) under the allele model (C677T: T vs. C; A1298C: C vs. A), dominant model (C677T: CT *+* TT vs. CC; A1298C: AC *+* CC vs. AA), and recessive model (C677T: TT vs. CC *+* CT; A1298C: CC vs. AA *+* AC). The heterogeneity between included studies was evaluated by the *Q*-test. *P* \> 0.1 indicates that there is no significant heterogeneity. I^2^ statistic was also calculated to quantify the heterogeneity: I^2^ \< 25 %, I^2^ = 25--50%, I^2^ = 50--75% and I^2^ \> 75%, indicated no heterogeneity, moderate heterogeneity, large heterogeneity, and extreme heterogeneity, respectively. When *P~Q~* \> 0.1 and I^2^ \< 25%, the heterogeneity was considered to be nonsignificant and then the pooled OR and 95% CIs could be assessed by the fixed-effects model; otherwise, the random-effects model was used. Subgroup analyses were performed based on ethnicity (Caucasians and Asians), study type (prospective and retrospective), clinical outcome (objective response and TRG) and chemotherapy regimen, and only for groups reported in at least three independent studies. The sensitivity analysis was carried out by sequential omission of individual studies to assess the stability of the results. The publication bias was detected using Egger\'s regression test and Begg--Mazumdar adjusted rank correlation test. *P* \< 0.05 indicated the presence of potential publication bias. Additionally, the cumulative meta-analysis was also carried out chronologically by publication year to observe the trend in estimated risk effect. All statistical analyses were conducted with the software STATA version 12.0 (Stata Corporation, College Station, TX, USA).
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